Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 4Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2NET 2Endocrine 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 6Neoplasms 4Breast Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Mesothelioma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2Advanced Solid Tumor 2Stomach Neoplasms 1Solid Tumors 1Recurrence 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Major Advanced Solid Tumors Other Than Colorectal 1Leukemia 1Glioblastoma 1Gastrointestinal Malignancies 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1ADVANCED SOLID TUMORS 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Neoplasms × PM 01183 × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
122 enrolled 19 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT01980667 2017-01-26

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

PharmaMar

Phase 1 Completed
41 enrolled
Tumor-Agnostic

Neoplasms

NCT01970553 2015-04-01

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
47 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡